PMC4634743_01
Transverse CT scan of the oral cavity showing an oral tumor at diagnosis (a) and 30 days after the initiation of bortezomib treatment (b)
40364_2015_53_Fig1_HTML.jpg
PMC4634743_01_40364_2015_53_Fig1_HTML.jpg
Fig1
A computed tomography (CT) demonstrated a bulky tumor localized in the mucosa of the oral cavity (Fig. 1a), without enlargement of the systemic lymph nodes. One week after the initiation of bortezomib, a marked regression of the oral tumor was observed, and one month after its initiation, no significant swelling of the oral cavity was detected (Fig. 1b).
a Hematoxylin and eosin staining showing large lymphoid cells with centroblastic morphology (X400). Cells of the oral tumor (X200) were immunohistologically positive for b CD138 and c CD38, d MUM-1, and were negative for e CD20, f CD79a, g EBV-encoded RNA in situ hybridization (EBER-ISH) and h HHV8. i The Ki-67 proliferation index was almost 100 %
40364_2015_53_Fig2_HTML.jpg
PMC4634743_01_40364_2015_53_Fig2_HTML.jpg
Fig2
Biopsy of the oral mass showed diffuse proliferation of large lymphoid cells (Fig. 2a) with centroblastic morphology, which were positive for CD138 (Fig. 2b), CD38 (Fig. 2c), CD56, and MUM-1 (Fig. 2d) and negative for CD20 (Fig. 2e), CD79a (Fig. 2f), CD3 and BCL-6. EBV-encoded RNA in situ hybridization (EBER-ISH) (Fig. 2g) and HHV8 (Fig. 2h) were negative. The Ki-67 proliferation index was almost 100 % (Fig. 2i).